| Reid et al,, IDWeek 2012, October 2012Safety and Pharmacokinetics of MGCD290, an Oral Fungal Hos2 Inhibitor, Alone and in Combination with Fluconazole: Single and Multiple Ascending Dose Studies in Healthy Subjects (290-001, 002, 003, 004) |  |
| Besterman et al., ICAAC Annual Meeting, September 2012MGCD290, an Oral Fungal Hos2 Inhibitor, Enhances the Antifungal Properties of Fluconazole Following Multiple- or Single-Dose Oral Administration in Pre- and Post-Infection Settings | |
| Reid, G. et al. 50th ICAAC Annual Meeting, September 2010Multiple ascending dose phase I studies in healthy subjects demonstrate safety and pharmacokinetics of MGCD290, an oral fungal Hos2 inhibitor +/- fluconazole | |
| Pfaller MA et al J Clin Microbiol. 2009 47(12):3797-804.Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens | |
| Nguyen, T. D., et al., 49th Annual ICAAC Meeting, September 2009A novel small molecule antifungal agent, MGCD290, modulates azole activity in yeast through specific inhibition of the histone deacetylase Hos2 | |
| Martell, L. et al., 49th Annual ICCAC Meeting, September 2009Multiple phase I studies in healthy subjects demonstrate safety and pharmacokinetics of MGCD290, an oral fungal Hos2 inhibitor +/- fluconazole | |
| Diekema, D. et al. ICAAC/IDSA Annual Meeting, October 2008Combination testing of MGCD290, a fungal histone deacetylase inhibitor, with azole antifungals against a large collection of clinical fungal isolates | |
| Nguyen, D. T. et al. ICAAC/IDSA Annual Meeting, October 2008In vivo properties of MGCD290, an antifungal Hos2 histone deacetylase (HDAC) enzyme inhibitor | |
| Akache, B. et al., ASM General Meeting, May 21-25, 2007MG290, a selective HDAC inhibitor, potentiates the anticandidal activity of ergosterol synthesis inhibitors, but not of compounds with other mechanisms of action | |
| Nguyen, D. et al., ASM General Meeting, May 21-25, 2007(English) MG290, a selective HDAC inhibitor, increases the post-antifungal effect and cidal potential of azoles in Candida species and decreases the frequency of azole resistance in candida glabrata | |
| Yeung, Bonnie et al. ECCMID, March 31-April 3, 2007, Munich(English) Effects of MG3290, a Selective Histone Deacetylase (HDAC) Inhibitor, on Azole Resistance in Candida glabrata | |
| Campeol, N. et al., 46th ICAAC Annual Meeting, Sept 27-30, 2006, San FranciscoPotentiation of Azole Antifungal Activity of MG3290, a Selective Histone Deacetylase (HDAC) Inhibitor in Candida glabrata | |
| Yeung, B. et al, 3rd Annual N.A. Genetic ABC Workshop, Sept 21-22, 2006, Frederick, MDPotentiation of Azole Antifungal Activity of MG3290, a Selective Histone Deacetylase (HDAC) Inhibitor, in Azole-Resistant Mutants of Candida glabrata | |
| Nguyen, D.T. et al. ASM General Meeting, May 21-25, 2006Synergy of MG3290, a Histone Deacetylase Inhibitor (HDAC1), with Azole Antifungals in Candida species and Aspergillus fumigatus. Effects on HDAC activity and ERG11 and CDR1/2 gene expression | |
| Bedard, J. et al, 45th ICCAC, December 16-19, 2005, Washington DCSynergism of Histone Deacetylase (HDAC) Inhibitors with Ketoconazole in Candida albicnas and Candida glabrata. Relationship to their Effects on HDAC Activity in Protoplasts | |
| Hu, Wenqi et al, 45th ICCAC, December 16-19, 2005, Washington DCSynergism of Histone Deacetylase (HDAC) inhibitors with Ketoconazole in Aspergillus fumigatus. Relationship to Inhibitory Effects on HDAC Activity in Protoplasts | |